Learn More >

Ministry Status: Recovery

The ministry is resuming regular operations and supporting health sector stabilization.

Publicly Funded Drug Programs

Inherited Metabolic Diseases Program

Through the Inherited Metabolic Diseases (IMD) Program, the Ministry of Health and Long-Term Care covers the full cost of certain outpatient drugs, supplements and specialty foods used in the treatment of specific inherited metabolic disorders. The IMD Program covers:

  • Specific drugs and supplements
  • Modified L-Amino Acid mixtures ("medical foods")
  • Special Low Protein Foods
  • Other supplements
  • Infant Feeds
  • Complete Enteral Feeds

Only the metabolic disorders and Funded Products as listed in the List of Disorders, Covered Drugs, Supplements and Specialty Foods are covered by the IMD Program. As a means to ensure that appropriate treatments are being provided to IMD Program patients, special treatment facilities have been designated to distribute the Funded Products. Decisions about what products are funded are made by the Executive Officer of Ontario Public Drug Programs based on expert advice provided by an advisory committee. For more information on metabolic conditions, visit the ministry's website on Newborn Screening.

The IMD Program will cover the costs of the foregoing types of products ("Funded Products"), provided that the patient:

  • Is an Ontario resident with valid Ontario Health Insurance (OHIP); 
  • Has been diagnosed with an inherited metabolic disorder for which one of the Funded Products has been prescribed as a treatment;
  • Is under the care of a physician from a designated treatment centre;
  • Obtains the Funded Products from a designated treatment centre.

To register a patient in the IMD Program, an application and consent form must be completed and submitted to the ministry.

Fabrazyme (agalsidase beta) and Replagal (agalsidase alfa) for the treatment of Fabry Disease

Effective September 2013 the funding of agalsidase for Fabry Disease was transitioned from the national process through the University Health Network (UHN) to the Ontario Public Drug Programs (OPDP). The Canadian Fabry Disease Initiative (CFDI) will continue to assess new patient applications, annual renewals, and manage the ordering of enzyme replacement therapy (ERT) from the manufacturers.  All current and new patients must continue to be eligible for ERT according to the current Canadian Fabry Disease Treatment Guidelines.

To apply for treatment funding, an assessment or renewal form must be completed and submitted to the CFDI.

For more information, please contact:

Canadian Fabry Disease Initiative (CFDI)
Shanas Mohamed
Ontario Coordinator for CFDI
Metabolic Genetics & Fabry Disease Clinic
University Health Network Peter Munk Cardiac Centre
Tel: 416-340-3721
Fax: 416-340-3226
E-mail: shanas.mohamed@uhn.ca

Aldurazyme (laronidase) for the treatment of Hurler and Hurler-Scheie forms of Mucopolysaccharidosis I (MPS I):

Effective October 1, 2011, the administration and funding of laronidase was transitioned from the University Health Network (UHN) to the IMD program.  All current and new patients will be enrolled in the IMD program. Patients must meet the funding criteria as outlined in the reimbursement guidelines:

Inquiries regarding the IMD Program should be directed to :

Ontario Public Drug Programs
5700 Yonge Street, 3rd Floor
Toronto ON  M2M 4K5
Fax: 416-327-8123
Email: PublicDrugPrgrms.moh@ontario.ca

For More Information

Call ServiceOntario, Infoline at:
1–866–532–3161 (Toll–free)
In Toronto, (416) 314–5518
TTY 1–800–387–5559.
In Toronto, TTY (416)327–4282
Hours of operation: Monday to Friday, 8:30am – 5:00pm

  • Connect With Us
Facebook Twitter YouTube RSS